Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Evaluate Safety and Efficacy of DB-020 to Protect Hearing in Patients Receiving Cisplatin for Cancer Treatment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04262336
Recruitment Status : Recruiting
First Posted : February 10, 2020
Last Update Posted : July 21, 2020
Sponsor:
Information provided by (Responsible Party):
Decibel Therapeutics

Brief Summary:
The purpose of this study is to evaluate whether DB-020 administered via an injection in the middle ear prevents hearing loss in participants who will receive high doses of cisplatin as part of their treatment for cancer.

Condition or disease Intervention/treatment Phase
Ototoxicity Drug: DB-020 Drug: Placebo Phase 1

Detailed Description:

Cisplatin is a widely used and effective chemotherapy in the treatment of adult and pediatric solid tumors, including bladder, testicular, head and neck, and lung cancers. Serious side effects of cisplatin treatment include ototoxicity. To date, no approved therapy to prevent or treat ototoxicity exists for people receiving cisplatin treatment, which remains the most common dose-limiting side effect associated with cisplatin administration.

Participants who will be undergoing cancer treatment with high doses of cisplatin every 21 or 28 days will receive IT injection with one ear receiving DB-020 and one ear receiving placebo during each administration. The study will comprise 2 parts. In Part A, eligible participants will be randomized to one of two doses of DB-020. In Part B, participants will be treated with a single dose of DB-020, as selected from data collected in Part A. In both Parts A and B, the ear receiving DB-020 or placebo will be randomized. The choice of dose in Part B will depend on the data from Part A. If appropriate safety and efficacy is observed at either dose level, the Sponsor has the option of dosing at one of these concentrations either unilaterally (ie, with placebo administered in the contralateral ear) or bilaterally (ie, open-label DB-020 administered to both ears) in Part B.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 70 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:

Part A: DB-020 12% right ear/placebo left ear; DB-020 12% left ear/placebo right ear; DB-020 25% right ear/placebo left ear; DB-020 25% left ear/placebo right ear on Day 1 of every 21 or 28 day cisplatin cycle for up to 6 cycles until cisplatin administration is discontinued

Part B: DB-020 12% both ears or DB-020-25% both ears on Day 1 of every 21 or 28 day cisplatin cycle for up to 6 cycles until cisplatin administration is discontinued

Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: Double blind
Primary Purpose: Prevention
Official Title: Phase 1b Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Repeated Doses of DB-020 in Patients Receiving Cisplatin
Actual Study Start Date : February 21, 2020
Estimated Primary Completion Date : September 2021
Estimated Study Completion Date : March 2022

Arm Intervention/treatment
Active Comparator: DB-020 for Injection, 12%/placebo
dosage
Drug: DB-020
Injectable sterile viscous solution of DB-020 and sodium hyaluronate in sterile water
Other Name: Sodium Thiosulfate (STS) pentahydrate formulated in sodium hyaluronate

Drug: Placebo
Injectable sterile viscous solution of sodium hyaluronate in sodium chloride
Other Name: sodium hyaluronate in sodium chloride

Active Comparator: DB-020 for Injection, 25%/placebo
dosage
Drug: DB-020
Injectable sterile viscous solution of DB-020 and sodium hyaluronate in sterile water
Other Name: Sodium Thiosulfate (STS) pentahydrate formulated in sodium hyaluronate

Drug: Placebo
Injectable sterile viscous solution of sodium hyaluronate in sodium chloride
Other Name: sodium hyaluronate in sodium chloride




Primary Outcome Measures :
  1. Number of patients with treatment-emergent Adverse Events (TEAEs) and/or abnormal changes from baseline in clinical laboratory abnormalities and/or vital signs and/or ECG assessments [ Time Frame: From screening/baseline (Day -28 to Day -2) or day of first dose of DB-020 (Cycle 1 Day 1) for up to 6 cycles (21 or 28 day cycles) through End of Treatment Visit (28 days after last dose of study drug), up to 196 Days after first dose of study drug ]
    To investigate the safety and tolerability of DB-020 when given intratympanically to patients receiving cisplatin chemotherapy treatment


Secondary Outcome Measures :
  1. Incidence of Ototoxicity measured by American Speech-Language-Hearing Association (ASHA) criteria [ Time Frame: Baseline (Day -5 to Day -1) for up to 6 cycles (21 or 28 day cycles) through End of Treatment Visit (28 days after last dose of study drug), up to 196 Days after first dose of study drug ]
    Air conduction audiometry consists of a set of pure tones presented to the patient through small speakers in a headset, played at carrier frequencies ranging from 250 to 16,000 Hz. Pure tone thresholds are recorded for each frequency tested. Ototoxicity will be defined according to the American Speech-Language-Hearing Association (ASHA) criteria for significant ototoxic change. Significant ototoxic change must meet one of the following three criteria: (i) ≥20 dB decrease at any one test frequency, (ii) ≥10 dB decrease at any two adjacent frequencies, or (iii) loss of response at three consecutive frequencies where responses were previously obtained. The presence of ototoxicity will be calculated for each ear

  2. Changes from Baseline in Pure Tone Threshold Values compared to End of Treatment [Changes in Hearing] [ Time Frame: Baseline (Day -5 to Day -1) for up to 6 cycles (21 or 28 day cycles) through End of Treatment Visit (28 days after last dose of study drug), up to 196 Days after first dose of study drug ]
    Air conduction audiometry consists of a set of pure tones presented to the patient through small speakers in a headset, played at carrier frequencies ranging from 250 to 16,000 Hz. Pure tone thresholds are recorded for each frequency tested. Higher values indicate a greater degree of hearing impairment. Changes from baseline values will be calculated for each frequency and ear as the reported pure tone threshold value minus the baseline value. A negative change from baseline indicates hearing loss

  3. Changes from Baseline in Tinnitus Functional Index (TFI) Total Score compared to End of Treatment [Changes in Hearing] [ Time Frame: Baseline (Day -5 to Day -1) for up to 6 cycles (21 or 28 day cycles) through End of Treatment Visit (28 days after last dose of study drug), up to 196 Days after first dose of study drug ]
    The TFI is a 25-item self-assessment scale comprised of eight subscales (intrusiveness, sense of control, cognitive, sleep, auditory, relaxation, quality of life, and emotional) measuring the impact of tinnitus. Items are scored on a range of 0 to 10. The TFI Total Score is calculated as the mean of the 25 individual item scores multiplied by 10. The Total Score can range from 0 to 100. Higher scores indicate a greater degree of tinnitus-related impairment. Change from baseline values will be calculated as the reported TFI value minus the baseline value. A positive change from baseline indicates more tinnitus-related impairment

  4. Changes from Baseline in Distortion Product Otoacoustic Emission (DPOAE) Values compared to End of Treatment [Changes in Hearing] [ Time Frame: Baseline (Day -5 to Day -1) and Cycle 1 Day 1 (21 or 28 day cycles) and End of Treatment Visit (28 days after last dose of study drug), up to 196 Days after first dose of study drug ]
    Distortion product otoacoustic emission (DPOAE) is defined as sound generated within the cochlea by stimulating the ear with two simultaneous tones of different frequency. DPOAEs serve as an objective measure of hearing sensitivity. Tones will be played from low to high frequencies (1 to 4 kHz) at soft to moderate levels to assess responses at different regions of the inner ear. DP levels will be recorded for each frequency and ear. Higher DP levels indicate more sensitive hearing. Change from baseline values will be calculated as the reported DP level value minus the baseline value. A negative change from baseline indicates less sensitive hearing

  5. Changes from Baseline in Words-in-Noise (WIN) Values compared to End of Treatment [Changes in Hearing] [ Time Frame: Baseline (Day -5 to Day -1) and Cycle 1 Day 1 (21 or 28 day cycles) and End of Treatment Visit (28 days after last dose of study drug), up to 196 Days after first dose of study drug ]
    The WIN test is a series of trials to measure the ability to accurately recognize speech in noise. In each trial, a series of 5 words is read to the listener with the instruction to repeat each word. The number of correct responses is captured. Trials are presented at 7 signal-to-noise ratios, from 0 to 24 dB, in steps of 4 dB. WIN thresholds are then calculated for each ear using the Spearman-Kaerber method. Higher WIN thresholds indicate better word recognition. Change from baseline values will be calculated for each ear as the reported WIN threshold value minus the baseline value. A negative change from baseline indicates worse word recognition

  6. Changes from Baseline in Hearing Handicap Inventory for Adults (HHIA) Total Score compared to End of Treatment [Changes in Hearing] [ Time Frame: Baseline (Day -5 to Day -1) and Cycle 1 Day 1 (21 or 28 day cycles) and End of Treatment Visit (28 days after last dose of study drug), up to 196 Days after first dose of study drug ]
    The Hearing Handicap Inventory for Adults (HHIA) is a 25-item self-assessment scale comprised of two subscales (emotional and social/situational) measuring the impact of hearing loss. Items are scored on a range of 0 to 4. The HHIA Total Score is calculated as the sum of the 25 individual item scores. The HHIA Total Score can range from 0 to 100. Higher scores indicate a greater degree of hearing impairment. Change from baseline values will be calculated as the reported HHIA value minus the baseline value. A positive change from baseline indicates more hearing impairment

  7. Plasma Concentrations of DB-020 [ Time Frame: Predose and 0.25 hours prior to cisplatin administration on Cycle 1 Day 1 (21 or 28 day cycles) ]
  8. Maximum observed plasma concentration (Cmax) of free (unbound) cisplatin [ Time Frame: 0.25 hours predose, mid-point of IV infusion, end of infusion, 0.25, 0.5, 1 & 2 hours postdose on Day 1 of each cycle (21 or 28 day cycles) ]
  9. Area under the plasma concentration-time curve (AUC 0-inf) of free (unbound) cisplatin [ Time Frame: 0.25 hours predose, mid-point of IV infusion, end of infusion, 0.25, 0.5, 1 & 2 hours postdose on Day 1 of each cycle (21 or 28 day cycles) ]
  10. Time to reach maximum observed plasma concentration (tmax) of free (unbound) cisplatin [ Time Frame: 0.25 hours predose, mid-point of IV infusion, end of infusion, 0.25, 0.5, 1 & 2 hours postdose on Day 1 of each cycle (21 or 28 day cycles) ]
  11. Half-life (t1/2) of plasma concentrations of free (unbound) cisplatin [ Time Frame: 0.25 hours predose, mid-point of IV infusion, end of infusion, 0.25, 0.5, 1 & 2 hours postdose on Day 1 of each cycle (21 or 28 day cycles) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Ability to communicate with medical team and staff, willingness to participate in the study, give written informed consent, comply with the study restrictions
  • Adults aged 18 years, inclusive, or older
  • Treatment for cancer with Intervenous cisplatin once every 21 or 28 days
  • Plan to receive a minimum cumulative dose of cisplatin of ≥ 280 mg/m2 over at least three cycles
  • Concomitant use of other chemotherapy and radiation is permitted except investigational agents and/or radiation > 35 Grays involving the cochlear area
  • Male patients, their female partner(s), and female patients of childbearing potential must agree to use 2 forms of contraception, 1 of which must be a barrier method, during the study and for 90 days after the last study drug administration.
  • Male and female patients who consider themselves abstinent, and who agree to remain abstinent during the study and for 90 days after the last study drug administration
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2
  • Anticipated survival > 1 year
  • Normal or not clinically significant otoscopic findings in both ears
  • Patient has read, understood, and voluntarily signed the informed consent form.

Exclusion Criteria:

  • Female or male patients with female partners who are pregnant, lactating, or planning to attempt to become pregnant during this study or within 90 days after last dose of study drug
  • Prior treatment with a cisplatin regimen
  • Signs of disturbed integrity of the tympanic membrane on otoscopy or tympanometry
  • History of congenital hearing loss
  • History of otological surgery (excluding myringotomy tubes or simple tympanoplasty)
  • History of sudden hearing loss
  • History of conductive hearing loss > 10 decibels at 2 frequencies in either ear
  • Diagnosis of Meniere's disease
  • Diagnosis of autoimmune middle ear disease
  • Hearing loss greater than (not including) 45 decibels Hearing Loss averaged at 6 and 8 kilohertz in either ear
  • Asymmetry in hearing thresholds between left and right ear equal to or exceeding 20 decibels at any single frequency or 10 decibels at any 3 consecutive frequencies, up to and including 8 kilohertz
  • Previous radiation exposure > 35 Grays to all or part of the cochlea
  • Consumption of > 6 grams of salicylate or > 5 grams of acetaminophen (paracetamol) per day for the past month, or aminoglycoside use in the past month
  • Use of any investigational drug or device within 30 days prior to the first dose of study medication (6 months for biologic therapies) or 5 half-lives of the investigational drug, if known, whichever time is longer
  • History of any significant drug allergy (such as anaphylaxis or hepatotoxicity) and/or allergy to the excipients of the study medications
  • Presence of hepatitis C antibody with reflex hepatitis C virus (HCV) RNA testing (if anti-HCV is positive), hepatitis B surface antigen, or HIV antibodies 1 and 2

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04262336


Contacts
Layout table for location contacts
Contact: Heather Wolff, BA (617) 370-8701 hwolff@decibeltx.com

Locations
Layout table for location information
United States, Colorado
University of Colorado Not yet recruiting
Denver, Colorado, United States, 80045
Contact: Elaine Lam, MD    720-848-0273    elaine.lam@cuanschutz.edu   
United States, Florida
University of Miami Health System Not yet recruiting
Miami, Florida, United States, 33136
Contact: Adrien A Eshraghi, MD    305-243-1484    aeshraghi@med.miami.edu   
United States, Illinois
The University of Chicago Medical Center Not yet recruiting
Chicago, Illinois, United States, 60637
Contact: Ari Rosenberg, MD    772-702-4400    arirosenberg@medicine.bsd.uchicago.edu   
United States, Kansas
University of Kansas Medical Center Not yet recruiting
Kansas City, Kansas, United States, 66160
Contact: Bryan Humphrey, RRT-NPS    913-588-3759    bhumphrey@kumc.edu   
United States, Missouri
Saint Louis University Not yet recruiting
Saint Louis, Missouri, United States, 63110
Contact: Gregory Ward, MD    314-577-8884    greg.m.ward@health.slu.edu   
United States, Montana
SCL Health St. Vincent Healthcare Recruiting
Billings, Montana, United States, 59101
Contact: Patrick W Cobb, MD    406-238-6290    patrick.cobb@sclhealth.org   
United States, West Virginia
WVU Cancer Institute Recruiting
Morgantown, West Virginia, United States, 26506
Contact: Anne Schnatterly, BSN    304-293-7374    wvucictru@hsc.wvu.edu   
Australia, New South Wales
The Crown Princess Mary Cancer Care Centre Recruiting
Westmead, New South Wales, Australia, 2145
Contact: Melville da Cruz, MD    +61 2 9845 6025    melville.dacruz@sydney.edu.au   
Australia, Queensland
Queensland Head and Neck Cancer Centre Recruiting
Woolloongabba, Queensland, Australia, 4102
Contact: Ben Panizza, MD    +61 7 3176 4238    ben@panizza.com.au   
Australia, Victoria
Peter MacCallum Cancer Centre Not yet recruiting
Melbourne, Victoria, Australia, 3000
Contact: Robert Tobler    +61 3 8559 5000    Robert.Tobler@petermac.org   
Oncology and Palliative Care Research Recruiting
Melbourne, Victoria, Australia, 3065
Contact: Nadia Ranieri    +61 3 9231 3167    Nadia.RANIERI@svha.org.au   
Sponsors and Collaborators
Decibel Therapeutics
Investigators
Layout table for investigator information
Study Chair: John Keilty, MS Decibel Therapeutics
Layout table for additonal information
Responsible Party: Decibel Therapeutics
ClinicalTrials.gov Identifier: NCT04262336    
Other Study ID Numbers: DB-020-002
1111-1243-8337 ( Other Identifier: WHO )
First Posted: February 10, 2020    Key Record Dates
Last Update Posted: July 21, 2020
Last Verified: July 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Decibel Therapeutics:
Ototoxicity
Hearing loss
Chemotherapy-induced
Additional relevant MeSH terms:
Layout table for MeSH terms
Sodium thiosulfate
Hyaluronic Acid
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs
Viscosupplements
Protective Agents
Antidotes
Antioxidants
Molecular Mechanisms of Pharmacological Action
Antitubercular Agents
Anti-Bacterial Agents
Anti-Infective Agents
Chelating Agents
Sequestering Agents